CONSTILAC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Constilac, and what generic alternatives are available?
Constilac is a drug marketed by Alra and is included in one NDA.
The generic ingredient in CONSTILAC is lactulose. There is one drug master file entry for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the lactulose profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Constilac
A generic version of CONSTILAC was approved as lactulose by PHARM ASSOC on July 30th, 1996.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CONSTILAC?
- What are the global sales for CONSTILAC?
- What is Average Wholesale Price for CONSTILAC?
Summary for CONSTILAC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 40 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,397 |
| DailyMed Link: | CONSTILAC at DailyMed |
Recent Clinical Trials for CONSTILAC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tampa General Hospital | Phase 4 |
US Patents and Regulatory Information for CONSTILAC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alra | CONSTILAC | lactulose | SOLUTION;ORAL | 071054-001 | Jul 26, 1988 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
